An Early Phase 1 interventional study of REGEND007 in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Regend Therapeutics. Recruiting at 1 site in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-23.
Sponsored by Regend Therapeutics · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China — 111 open to participants now, 128 under way, 16 of them phase 3. Pulmonary Disease, Chronic Obstructive · China.
Among the 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China, this one is the 274th largest by planned enrollment of the 289 interventional ones that give a count, is one of 37 that started in 2026, is one of 29 in phase 1, reaches primary completion later than 48 of the 127 other live ones, and was the 364th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →111 of the 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China are open now. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18+
Eli Lilly and Company · Sites in China, United States, Argentina and 15 more countries
Ages 40–75
Tiantian Li · Sites in China
Ages 40–80
Nanfang Hospital, Southern Medical University · Sites in China
Ages 30–85
Shanghai Pulmonary Hospital, Shanghai, China · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
407 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 42 · Phase 3 67 · Phase 4 33
First in 2000; this study’s year is marked. 37 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12 is below the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 160 across the 289 interventional studies, 500 across the 118 observational. Of the 183 that completed or were terminated, 48 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
162 of 407 have an industry lead sponsor. The 10 most frequent:
Regend Therapeutics is the lead sponsor of 11 studies on the registry; 5 are open to participants now.
Regend Therapeutics has 4 studies filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
30 of the studies in Pulmonary Disease, Chronic Obstructive with a site in China that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07464587Phase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease | 2027-02 |
| NCT07147946Phase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease | 2027-03 |
| NCT07658339Phase 3Haisco Pharmaceutical Group Co., Ltd.A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of HSK39004 Inhalation Suspension in Patients With COPD | 2027-06-11 |
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT07583849Phase 3Haisco Pharmaceutical Group Co., Ltd.A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment of COPD | 2027-09-30 |
Add all 30 to your calendar (.ics) → With an account.
Among the 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide with the characterization of obstructed airflow. In a large number of patients, diffusion function is impaired along with the progression of disease. REGEND007 cell therapy, comprised of airway basal cells with ability to regenerate lung tissue, is promising to COPD treatment. A prospective, single-arm, dose-escalation exploratory clinical study to evaluate the safety, tolerability and preliminary efficacy of different doses of REGEND007 cell therapy administered by intravenous infusion in the treatment of COPD, and to recommend appropriate treatment doses for subsequent clinical studies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: REGEND007
This study's intravenous infusion dose escalation protocol is based on a 3+3 dose escalation design, with a total of 4 dose groups. Each group included 3 subjects, and the dose is gradually increased until the maximum tolerated dose (MTD) or the maximum administered dose (MAD) is reached.
The incidence and severity of drug-related adverse events (AEs)
All adverse medical events that occur from the time the subject signs the informed consent form. These can manifest as symptoms, signs, diseases, or abnormal laboratory test results, but they do not necessarily have a causal relationship with the investigational drug
Time frame: Within 12 weeks after administration
The time of the first occurrence of acute exacerbation of COPD (AECOPD) after administration
The time of the first occurrence of acute exacerbation of COPD (AECOPD) after administration is an important indicator for assessing the severity and prognosis of the disease.
Time frame: Within 12 weeks after the last administration
The changes in the annual incidence of AECOPD after administration compared to before administration
The changes in the annual incidence of AECOPD after administration compared to before administration is an important indicator for assessing the severity and prognosis of the disease.
Time frame: 12 weeks after administration
The change in the forced vital capacity (FVC) actual-to-predicted ratio compared to baseline
FVC is the full amount of air that can beexhaled with effort in a complete breath
Time frame: 24 hours after administration, 4 and 12 weeks after the last administration
The changes in forced expiratory volume in one second (FEV1) actual-to-predicted ratio compared to baseline
FEV1 is the volume of breath exhaled with effort in one second.
Time frame: 24 hours after administration, 4 and 12 weeks after the last administration.
The changes in the carbon monoxide diffusion capacity (DLCO) actual-to-predicted ratio compared to baseline
DLCO is a measure of the conductance of CO across the alveolar-capillary membrane and its binding with hemoglobin.
Time frame: 24 hours after administration, 4 and 12 weeks after the last administration.
Ratio of DLCO to lung volume (DLCO/VA))
DLCO/VA is also known as the diffusion constant, since the diffusion amount is affected by the alveolar ventilation volume, a decrease in alveolar ventilation volume can lead to a reduction in DLCO. Therefore, this value is often used for correction to eliminate the influence of lung volume on the diffusion amount.
Time frame: 24 hours after administration, 4 and 12 weeks after the last administration.
The changes in the six-minute walk test (6MWT) compared to baseline
6MWT is one of the commonly used methods in clinical practice for assessing a patient's cardiac and pulmonary functions, which involves measuring the distance that a patient can walk quickly on a flat and hard surface within 6 minutes.
Time frame: 24 hours after administration, 4 and 12 weeks after the last administration.
The changes in the COPD assessment test (CAT) compared to the baseline.
CAT is a self-completed questionnaire tool by the patients, used to assess the extent to which the condition of chronic obstructive pulmonary disease affects their quality of life.
Time frame: 24 hours after administration, 4 and 12 weeks after the last administration.
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Oct 2026, 6 months after the start.
Of 158 industry-sponsored phase 1 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 9. This study's planned 6 months is above that.
Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 2 and three quarters within 11.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
Regend Therapeutics